Table 4.
Assessments of the influence of different issues on the price of a new drug (italic emphasis indicates correct responses, as determined by content experts)
| Issue | Most influential N (%) | Somewhat influential N (%) | Not influential N (%) | Don’t know N (%) |
|---|---|---|---|---|
| Insurance company policies | 139 (57.92) | 86 (35.83) | 5 (2.08) | 10 (4.17) |
| Rarity of the disease/condition | 100 (41.67) | 107 (44.58) | 13 (5.42) | 20 (8.33) |
| Government regulations | 67 (27.92) | 131 (54.58) | 22 (9.17) | 20 (8.33) |
| Number of other drugs for the disease/condition | 101 (42.08) | 108 (45.00) | 16 (6.67) | 15 (6.25) |
| Middlemen in the drug distribution system | 98 (40.83) | 107 (44.58) | 10 (4.17) | 25 (10.42) |
| Novelty of the drug’s mechanism | 72 (30.00) | 104 (43.33) | 42 (17.50) | 22 (9.17) |
| Financial incentives of healthcare providers | 43 (17.92) | 120 (50.00) | 48 (20.00) | 29 (12.08) |
| Cost of the drug’s development | 162 (67.50) | 65 (27.08) | 5 (2.08) | 8 (3.33) |
| Cost of marketing to consumers | 102 (42.50) | 111 (46.25) | 13 (5.42) | 14 (5.83) |
| Consumer demand | 87 (36.25) | 108 (45.00) | 31 (12.92) | 14 (5.83) |
| Cost of marketing to doctors | 65 (27.08) | 131 (54.58) | 29 (12.08) | 15 (6.25) |
| Population burden of the disease/condition | 46 (19.17) | 141 (58.75) | 31 (12.92) | 22 (9.17) |
| Safety and effectiveness of the drug | 22 (9.17) | 118 (49.17) | 76 (31.67) | 24 (10.00) |
| Safety and effectiveness of other drugs for the disease/condition | 15 (6.25) | 135 (56.25) | 66 (27.50) | 24 (10.00) |